Barclays Downgrades Pacira BioSciences to Equal-Weight, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has downgraded Pacira BioSciences (NASDAQ:PCRX) from Overweight to Equal-Weight and lowered the price target from $38 to $25.
July 03, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has downgraded Pacira BioSciences from Overweight to Equal-Weight and reduced the price target from $38 to $25, indicating a less optimistic outlook.
The downgrade from Overweight to Equal-Weight and the significant reduction in the price target from $38 to $25 by Barclays suggests a less favorable view on Pacira BioSciences' future performance. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100